xRead - September 2022

Wise et al.

Page 422

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.D.5. Study

design Study groups Clinical endpoint Conclusion

Symptom score improved in the treatment arm in year 1, but was not significantly different from control in year 2. Conjunctival provocation improved in the treatment group. Systemic reactions occurred in 7 treatment (14.6%) and 1 control patients.

Symptoms improved only in the highest dose group. There was no difference in medication use, SPT, or conjunctival provocation test. Local reactions were common. Systemic reactions occurred in 8.3% of patients.

No difference in SPT endpoint. Treatment group had less rhinoconjunctivitis symptoms and antihistamine use.

No significant difference in nasal provocation test. Subjective symptoms score improved. More local reactions (eczema) in treatment group.

Subjective symptoms,

conjunctival provocation test

Subjective symptoms, medication use, SPT,

conjunctival provocation test

SPT endpoint, subjective

symptoms, antihistamine use

Nasal provocation test,

subjective symptom score

1 Grass patches (n = 48);

2 Placebo patches (n = 50)

3. Medium-dose grass patches (n = 33); 2. High-dose grass patches (n = 33) 1 Grass patches (n = 15);

2 Placebo patches (n = 15)

1 Grass patches (n = 21);

2 Placebo patches (n = 17)

1. Placebo patches (n = 33);

2. Low-dose grass patches (n = 33);

Evidence for the use of transcutaneous/epicutaneous immunotherapy in the treatment of allergic rhinitis Study Year LOE Senti et al. 1715 2015 1b RDBPCT Adults: Senti et al. 1714 2012 1b RDBPCT Adults: Agostinis et al. 1713 2009 1b RDBPCT Children: Senti et al. 1712 2009 1b RDBPCT Adults:

LOE = level of evidence; RDBPCT = randomized double-blind placebo-controlled trial; SPT = skin-prick test.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.